BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer

BBOX1 是三阴性乳腺癌的新型致癌驱动因素

基本信息

  • 批准号:
    10393664
  • 负责人:
  • 金额:
    $ 39.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-15 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary Triple-Negative breast cancer (TNBC), which accounts for 15-20% of all breast cancer, represents an aggressive clinical history, development of distant metastasis, shorter survival and high mortaility rate compared with other subtypes of breast cancer. It is imperative to identity new therapeutic targets that are actionale in TNBC. Our lab has been focusing on studying a family of enzymes that uses oxygen, Fe2+ and 2-oxoglutarate (2-OG) for their enzymatic reactions. This enzyme family has been reported to be involved in the pathogenesis of cancers. We generated the custom siRNA library for all of 2-OG dependent enzymes and developed a stringent screening strategy by combining the functional readouts from both 2-D cell proliferation and 3-D soft agar growth assay with TNBC breast cancer cell lines. Our preliminary data show that gamma-butyrobetaine hydroxylase 1 (BBOX1) involved in carnitine biosynthesis pathway is essential for TNBC cell proliferation on 2-D and 3-D. Mechanistically, we show that BBOX1 binds with the calcium channel inositol-1,4,5-trisphosphate receptor type 3 (IP3R3), therefore promoting calcium release, mitochondrial function and glycolysis in TNBC. We hypothesize that BBOX1-IP3R3 signaling axis promotes TNBC by inducing calcium release and tumor metabolism. This is the first study directed at a pro-oncogenic function for BBOX1 in cancer, with our focus in TNBC. In Specific Aim 1, we will characterize the functional significance of BBOX1-IP3R3 signaling in TNBC. In Specific Aim 2, we will elucidate the molecular mechanism by which BBOX1-IP3R3 signaling promotes oncogenic phenotypes in TNBC. In Specific Aim 3, we will assess the therapeutic implications of targeting BBOX1 in TNBC xenografts and patient derived xenografts (PDXs). Successful completion of this proposal would establish the role of BBOX1 as a new oncogenic driver in TNBC and explore its therapeutic potential in this lethal disease.
项目摘要 三阴性乳腺癌(TNBC)占所有乳腺癌的15-20%,代表了侵袭性乳腺癌。 与其他化疗方案相比,化疗方案具有临床病史、远处转移、生存期短、死亡率高等特点 乳腺癌的亚型。鉴定在TNBC中有效的新治疗靶标是必要的。我们实验室 一直专注于研究一个家族的酶,使用氧,铁2+和2-酮戊二酸(2-OG)为他们的 酶促反应据报道,这种酶家族参与癌症的发病机制。我们 为所有2-OG依赖性酶生成了定制的siRNA库,并进行了严格的筛选 通过结合来自2-D细胞增殖和3-D软琼脂生长测定的功能读数的策略 TNBC乳腺癌细胞系。我们的初步数据表明,γ-丁基甜菜碱羟化酶1 在二维和三维上,参与肉毒碱生物合成途径的BBOX 1对于TNBC细胞增殖是必需的。 从机制上讲,我们发现BBOX 1与钙通道肌醇-1,4,5-三磷酸受体结合 3型(IP 3R 3),因此促进TNBC中的钙释放、线粒体功能和糖酵解。我们 假设BBOX 1-IP 3R 3信号传导轴通过诱导钙释放和肿瘤生长促进TNBC, 新陈代谢.这是第一项针对BBOX 1在癌症中的促癌功能的研究,我们的重点是 TNBC。在具体目标1中,我们将表征BBOX 1-IP 3R 3信号传导在TNBC中的功能意义。在 具体目标2,我们将阐明BBOX 1-IP 3R 3信号转导促进的分子机制 TNBC中的致癌表型。在具体目标3中,我们将评估靶向治疗的意义 TNBC异种移植物和患者来源的异种移植物(PDX)中的BBOX 1。成功完成这项提案将 建立BBOX 1作为TNBC中新的致癌驱动因子的作用,并探索其在这种致命疾病中的治疗潜力。 疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Qing Zhang其他文献

Qing Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Qing Zhang', 18)}}的其他基金

Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancer
鉴定 DCLK2-TBK1 信号轴作为肾癌的潜在治疗靶点
  • 批准号:
    10752584
  • 财政年份:
    2023
  • 资助金额:
    $ 39.39万
  • 项目类别:
A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer
一种新的组蛋白 H3 修饰调节乳腺癌的表观遗传编程和基因表达
  • 批准号:
    10607954
  • 财政年份:
    2022
  • 资助金额:
    $ 39.39万
  • 项目类别:
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer
BBOX1 是三阴性乳腺癌的新型致癌驱动因素
  • 批准号:
    10231769
  • 财政年份:
    2021
  • 资助金额:
    $ 39.39万
  • 项目类别:
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer
BBOX1 是三阴性乳腺癌的新型致癌驱动因素
  • 批准号:
    10577757
  • 财政年份:
    2021
  • 资助金额:
    $ 39.39万
  • 项目类别:
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer
探索 ZHX2 作为 pVHL 的新型底物和肾癌的致癌驱动因素
  • 批准号:
    10246844
  • 财政年份:
    2019
  • 资助金额:
    $ 39.39万
  • 项目类别:
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer
探索 ZHX2 作为 pVHL 的新型底物和肾癌的致癌驱动因素
  • 批准号:
    10065241
  • 财政年份:
    2019
  • 资助金额:
    $ 39.39万
  • 项目类别:
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer
探索 ZHX2 作为 pVHL 的新型底物和肾癌的致癌驱动因素
  • 批准号:
    9768410
  • 财政年份:
    2017
  • 资助金额:
    $ 39.39万
  • 项目类别:
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer
探索 ZHX2 作为 pVHL 的新型底物和肾癌的致癌驱动因素
  • 批准号:
    9382004
  • 财政年份:
    2017
  • 资助金额:
    $ 39.39万
  • 项目类别:
Role of the EglN2 Target FOXO3a in Breast Cancer
EglN2 靶点 FOXO3a 在乳腺癌中的作用
  • 批准号:
    8681385
  • 财政年份:
    2013
  • 资助金额:
    $ 39.39万
  • 项目类别:
Role of the EglN2 Target FOXO3a in Breast Cancer
EglN2 靶点 FOXO3a 在乳腺癌中的作用
  • 批准号:
    8639747
  • 财政年份:
    2013
  • 资助金额:
    $ 39.39万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 39.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了